Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Gregory Cheng
Eltrombopag, a Thrombopoietin- Receptor Agonist in the Treatment of Adult Chronic Immune Thrombocytopenia: A Review of the Efficacy and Safety Profile
Therapeutic Advances in Hematology
Hematology
Antiangiogenic Activity of a Concentrated Effective Microorganism Fermentation Extract
International Journal of Molecular Medicine
Medicine
Genetics
Related publications
Eltrombopag: An Update on the Novel, Non-Peptide Thrombopoietin Receptor Agonist for the Treatment of Immune Thrombocytopenia
Annals of Hematology
Medicine
Hematology
Relative Potency of the Thrombopoietin Receptor Agonists Eltrombopag, Avatrombopag and Romiplostim in a Patient With Chronic Immune Thrombocytopenia
British Journal of Haematology
Hematology
Tolerability and Efficacy of Eltrombopag in Chronic Immune Thrombocytopenia
Clinical and Applied Thrombosis/Hemostasis
Medicine
Hematology
The Efficacy and Safety of Romiplostim in Adult Patients With Chronic Immune Thrombocytopenia
Therapeutic Advances in Hematology
Hematology
Thrombopoietin Level Predicts Response to Treatment With Eltrombopag and Romiplostim in Immune Thrombocytopenia
American Journal of Hematology
Hematology
Switching Thrombopoietin Receptor Agonist Treatments in Patients With Primary Immune Thrombocytopenia
Therapeutic Advances in Hematology
Hematology
Thrombopoietin Receptor Agonists in Treatment of Idiopathic Thrompocytopenic Purpura (Primary Immune Thrombocytopenia): Efficacy and Safety in Everyday Clinical Practice
Klinicheskaya Onkogematologiya/Clinical Oncohematology
Oncology
Hematology
The Emergence of Thrombopoietin Receptor Agonists as a Novel Treatment for Immune Thrombocytopenia
European Oncology and Haematology
Oncology
Hematology
PP025 Thrombopoietin Receptor Agonist for Treatment of Adults With Chronic Immune Thrombocytopenic Purpura
International Journal of Technology Assessment in Health Care
Health Policy
